-
Innovation Ranking
Innovation Ranking – Hutchison China MediTech Ltd
Hutchmed China Ltd (Hutchmed) formerly known as Hutchison China MediTech Ltd is a biopharmaceutical company that discovers, develops, manufactures, and commercializes drugs for the treatment of solid tumors and hematological malignancies, and immunological disorders. It also offers over-the-counter (OTC) pharmaceuticals and consumer healthcare products. Hutchmed also provides R&D services to other companies. It has a broad pipeline of drug candidates indicated for the treatment of immunological diseases, besides novel oral drug candidates for various cancers and inflammation. It operates in...
-
Innovation Ranking
Innovation Ranking – CK Hutchison Holdings Ltd
CK Hutchison Holdings Ltd (CK Hutchison) is a conglomerate that offers a range of services for various industries including retail, infrastructure, energy, finance and investment and telecommunications sectors. Its offerings include port development, ship and cargo services, energy infrastructure services, mobile and broadband-related services, and manufacturing and distribution of healthcare, personal care, medicines, related products to the consumers. CK Hutchison also earns returns from investments in companies such as Hutchison Whampoa (China), Hutchison China MediTech, CK Life Sciences, TOM Group,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lifirafenib Maleate in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lifirafenib Maleate in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lifirafenib Maleate in Pancreatic Cancer Drug Details: Lifirafenib maleate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TNG-462 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNG-462 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNG-462 in Solid Tumor Drug Details: TNG-462 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HMPL-306 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HMPL-306 in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HMPL-306 in Myelodysplastic Syndrome Drug Details: HMPL-306 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HMPL-306 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HMPL-306 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HMPL-306 in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sovleplenib in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sovleplenib in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sovleplenib in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surufatinib in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surufatinib in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surufatinib in Lymphoma Drug Details: Surufatinib (Sulanda) is a potential antineoplastic and...